Bulk Manufacturer of Controlled Substances Application: Noramco, 8153-8154 [2025-01710]
Download as PDF
8153
Federal Register / Vol. 90, No. 15 / Friday, January 24, 2025 / Notices
Register pursuant to section 6(b) of the
Act on February 6, 2024 (89 FR 8243).
The last notification was filed with
the Department on April 16, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on June 28, 2024 (89 FR 54041).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
The last notification was filed with
the Department on July 9, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on September 26, 2024 (89 FR
78900).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Antitrust Division
khammond on DSK9W7S144PROD with NOTICES
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Undersea Technology
Innovation Consortium
Notice is hereby given that, on
October 10, 2024, pursuant to section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Undersea Technology Innovation
Consortium (‘‘UTIC’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, The Mason and Hanger
Group, Inc., Lexington, KY; EIZO
Rugged Solutions, Inc., Orlando, FL;
Carnegie Mellon University, Pittsburgh,
PA; KAIROS, Inc., California, MD;
Seemann Composites LLC, Gulfport,
MS; Bishop Ascendant, Inc., Caldwell,
NJ; and Calspan Systems LLC, Newport
News, VA, have been added as parties
to this venture.
Also, iXblue Defense Systems, Inc.,
Lincoln, RI; Integrated Consultants, Inc.,
San Diego, CA; SubUAS LLC,
Bridgewater, NJ; and Basic Engineering
Concepts & Technologies, Inc., White
Stone, VA, have withdrawn as parties to
this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and UTIC intends
to file additional written notifications
disclosing all changes in membership.
On October 9, 2018, UTIC filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on November 2, 2018 (83 FR 55203).
VerDate Sep<11>2014
16:21 Jan 23, 2025
Jkt 265001
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Consortium for Rare
Earth Technologies
Notice is hereby given that, on
October 11, 2024, pursuant to section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Consortium for Rare Earth Technologies
(‘‘CREaTe’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Alaska Range Resources,
LLC, Palmer, AK; and Orojo Resources
USA, LLC, Cleveland, GA, have been
added as parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open and CREaTe
intends to file additional written
notifications disclosing all changes in
membership.
On April 22, 2022, CREaTe filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on May 13, 2022 (87 FR 29384).
The last notification was filed with
the Department on July 18, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on October 11, 2024 (89 FR 82629).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2025–01701 Filed 1–23–25; 8:45 am]
BILLING CODE P
PO 00000
Frm 00039
[Docket No. DEA–1480]
Bulk Manufacturer of Controlled
Substances Application: Noramco
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
Noramco has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 25, 2025. Such
persons may also file a written request
for a hearing on the application on or
before March 25, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on October 8, 2024,
Noramco, 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUMMARY:
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
AGENCY:
[FR Doc. 2025–01704 Filed 1–23–25; 8:45 am]
[FR Doc. 2025–01714 Filed 1–23–25; 8:45 am]
DEPARTMENT OF JUSTICE
Fmt 4703
Sfmt 4703
Controlled substance
Gamma Hydroxybutyric
Acid.
Marihuana ........................
Tetrahydrocannabinols ....
Dihydromorphine .............
Hydromorphinol ...............
Amphetamine ..................
Lisdexamfetamine ...........
Methylphenidate ..............
Nabilone ..........................
Codeine ...........................
E:\FR\FM\24JAN1.SGM
24JAN1
Drug
code
Schedule
2010
I
7360
7370
9145
9301
1100
1205
1724
7379
9050
I
I
I
I
II
II
II
II
II
8154
Federal Register / Vol. 90, No. 15 / Friday, January 24, 2025 / Notices
Controlled substance
Drug
code
Schedule
9120
9143
9150
9193
9250
9300
9330
9333
9610
9620
9630
9639
9640
9652
9668
9780
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Dihydrocodeine ................
Oxycodone ......................
Hydromorphone ...............
Hydrocodone ...................
Methadone ......................
Morphine ..........................
Oripavine .........................
Thebaine ..........................
Opium extracts ................
Opium fluid extract ..........
Opium tincture .................
Opium, powdered ............
Opium, granulated ...........
Oxymorphone ..................
Noroxymorphone .............
Tapentadol ......................
[Docket No. DEA–1478]
Importer of Controlled Substances
Application: VHG Labs DBA LGC
Standards
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
The company plans to bulk
manufacture the listed controlled
substances as an Active Pharmaceutical
Ingredient for supply to its customers.
In reference to drug codes 7360
(Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025–01710 Filed 1–23–25; 8:45 am]
BILLING CODE P
VHG Labs DBA LGC
Standards has applied to be registered
as an importer of basic class(es) of
controlled substance(s). Refer to
Supplementary Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before February 24, 2025. Such
persons may also file a written request
for a hearing on the application on or
before February 24, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
SUMMARY:
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on November 1, 2024,
VHG Labs dba LGC Standards, 3
Perimeter Road, Manchester, New
Hampshire 03103–3341, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
khammond on DSK9W7S144PROD with NOTICES
Controlled substance
Drug code
Amineptine (7-[(10,11-dihydro-5Hdibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid) .......................................................
Mesocarb (N-phenyl-N′-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate) .............................................
3-Fluoro-N-methylcathinone (3-FMC) ....................................................................................................................................
Cathinone ..............................................................................................................................................................................
Methcathinone .......................................................................................................................................................................
4-Fluoro-N-methylcathinone (4-FMC) 1238 I N ....................................................................................................................
Para-Methoxymethamphetamine (PMMA), 1-(4-methoxyphenyl)-N-methylpropan-2-amine ................................................
Pentedrone (a-methylaminovalerophenone) .........................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ..........................................................................................................................
4-Methyl-N-ethylcathinone (4-MEC) ......................................................................................................................................
Naphyrone .............................................................................................................................................................................
N-Ethylamphetamine .............................................................................................................................................................
Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine) 1478 I N .............................................................................
N,N-Dimethylamphetamine ....................................................................................................................................................
Fenethylline ...........................................................................................................................................................................
Aminorex ................................................................................................................................................................................
4-Methylaminorex (cis isomer) ..............................................................................................................................................
4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-1595 I N methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine).
Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate) ......................................................................................................
Gamma Hydroxybutyric Acid .................................................................................................................................................
Methaqualone ........................................................................................................................................................................
Mecloqualone ........................................................................................................................................................................
Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine ......................................
Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4Hbenzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) ..................................
Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4Hbenzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine .........................................
Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine .................................
Diclazepam (7-chloro-5-(2-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one ......................
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ..........................................................................................................
SR-18 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ..............................................................................................
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ...................
5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone .......................
AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ............................
1-(4-Fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanon ........................................................................
VerDate Sep<11>2014
16:21 Jan 23, 2025
Jkt 265001
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
E:\FR\FM\24JAN1.SGM
24JAN1
Schedule
1219
1227
1233
1235
1237
1238
1245
1246
1248
1249
1258
1475
1478
1480
1503
1585
1590
1595
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
1727
2010
2565
2572
2780
2785
2786
2788
2789
6250
7008
7010
7011
7012
7014
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Agencies
[Federal Register Volume 90, Number 15 (Friday, January 24, 2025)]
[Notices]
[Pages 8153-8154]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-01710]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1480]
Bulk Manufacturer of Controlled Substances Application: Noramco
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Noramco has applied to be registered as a bulk manufacturer of
basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants, therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
March 25, 2025. Such persons may also file a written request for a
hearing on the application on or before March 25, 2025.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on October 8, 2024, Noramco, 500 Swedes Landing Road,
Wilmington, Delaware 19801-4417, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid............... 2010 I
Marihuana............................... 7360 I
Tetrahydrocannabinols................... 7370 I
Dihydromorphine......................... 9145 I
Hydromorphinol.......................... 9301 I
Amphetamine............................. 1100 II
Lisdexamfetamine........................ 1205 II
Methylphenidate......................... 1724 II
Nabilone................................ 7379 II
Codeine................................. 9050 II
[[Page 8154]]
Dihydrocodeine.......................... 9120 II
Oxycodone............................... 9143 II
Hydromorphone........................... 9150 II
Hydrocodone............................. 9193 II
Methadone............................... 9250 II
Morphine................................ 9300 II
Oripavine............................... 9330 II
Thebaine................................ 9333 II
Opium extracts.......................... 9610 II
Opium fluid extract..................... 9620 II
Opium tincture.......................... 9630 II
Opium, powdered......................... 9639 II
Opium, granulated....................... 9640 II
Oxymorphone............................. 9652 II
Noroxymorphone.......................... 9668 II
Tapentadol.............................. 9780 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances as an Active Pharmaceutical Ingredient for supply to its
customers. In reference to drug codes 7360 (Marihuana), and 7370
(Tetrahydrocannabinols), the company plans to bulk manufacture these
drugs as synthetic. No other activities for these drug codes are
authorized for this registration.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025-01710 Filed 1-23-25; 8:45 am]
BILLING CODE P